Compare IDYA & PCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | PCH |
|---|---|---|
| Founded | 2015 | 1903 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2019 | N/A |
| Metric | IDYA | PCH |
|---|---|---|
| Price | $34.38 | $40.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 6 |
| Target Price | ★ $49.18 | $45.67 |
| AVG Volume (30 Days) | ★ 943.7K | 537.1K |
| Earning Date | 02-12-2026 | 01-26-2026 |
| Dividend Yield | N/A | ★ 4.51% |
| EPS Growth | N/A | ★ 312.61 |
| EPS | N/A | ★ 0.82 |
| Revenue | $214,834,000.00 | ★ $1,115,571,000.00 |
| Revenue This Year | $2,662.86 | $3.66 |
| Revenue Next Year | N/A | $1.27 |
| P/E Ratio | ★ N/A | $48.68 |
| Revenue Growth | ★ 5377.66 | 5.40 |
| 52 Week Low | $13.45 | $36.82 |
| 52 Week High | $37.08 | $48.12 |
| Indicator | IDYA | PCH |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 51.39 |
| Support Level | $33.11 | $39.02 |
| Resistance Level | $34.45 | $40.35 |
| Average True Range (ATR) | 1.14 | 0.93 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 44.14 | 39.24 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.